HOME >> BIOLOGY >> NEWS
Horse breath testing to benefit racing

TWO new studies into horses' health could be of major importance to the economic health of the racing industry. The studies, at Adelaide University in Australia, include breath testing of horses and a new technique to help horses recover from serious tendon injury.

BREATH TESTING

Inflammatory Airway Disease (IAD) is a lower respiratory tract disease that causes problems in the horse racing industry. Studies have found that anything up to 50% of thoroughbred and standardbred racehorses in training suffer from the disease. However, the lack of overt symptoms that accompany it, other than a general poor performance on the track, means the disease often goes unnoticed.

Current diagnostic techniques are invasive, time-consuming and limited in their ability to detect lower airway disease. But a new "breath testing" technique could change all that.

Honours student Belinda Argent, under the supervision of Dr David Tivey (Department of Animal Science, Roseworthy Campus), has conducted trials of new testing procedures for IAD in horses, the results of which are eagerly awaited by veterinarians and trainers alike.

Ms Argent's study postulates that particular components of the breath expired by horses could be used as a direct marker of inflammatory disease occurring in the lungs.

"If this is proven to be the case," Ms Argent, says "it's expected that the test will not only be more sensitive diagnostically in the early stages of the disease, but also more readily accepted and utilised by trainers which will, in turn, hopefully be more effective in reducing the degree of damage caused by IAD in the horse racing industry."

The "breath test" method is stress-free for the animal and easily administered, using a simple bagging technique to trap breath and extract samples with a syringe for laboratory testing.

Trials have been conducted at Sydney's metropolitan racetracks and
'"/>

Contact: David Ellis
david.ellis@adelaide.edu.au
618-8303-3173
Adelaide University
6-Nov-2001


Page: 1 2 3

Related biology news :

1. Trojan Horses, xenon imaging and remote controlled genes
2. Horse owners should vaccinate horses, experts say
3. Horseshoe crabs survival rate after biomedical bleeding is high
4. Science: nanoscale Trojan Horse attacks cancer cells from within
5. Horseshoe Crab Research Center provides information to improve management
6. Horseshoe crab studies providing new insight into valuable ancient creatures
7. Continuing Research On Knee Surgery For Horses At Colorado State University Holds Promise Of Helping Humans With Osteoarthritis
8. Light Shed On Mystery Horse Disease
9. Horses Prefer Bridles That Have A Bit Missing
10. Veterinarians Input On Olympics Horse Events Has Had Global Impact
11. Trojan Horse Virus Controls Hiv Infection

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Horse breath testing benefit racing

(Date:7/2/2015)... Fingerprint Cards has received an order for its ... distributor World Peace Industrial Group (WPI), part of WPG Holdings. ... . Deliveries are planned to take place during Q3 ... manufacturers in Asia . The order value ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, ...
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/26/2015)... , June 26, 2015 ATL Technology, LLC, a ... with specialties in single use solutions, headquartered in ... Inc. (a California corporation with locations ... San Jose, Costa Rica ). This ... Rica with ATL Technology,s existing facility in ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2
(Date:7/3/2015)... Forskare kan ansöka ... http://www.openinnovationinscience.at till det återkommande utbildningsprogrammet "Lab ... i Wien .  ... forskare och vetenskapsmän som genomfördes av Ludwig ... utmaningar bristen på incitament för att undersöka ...
(Date:7/2/2015)... GLEN ELLYN, Ill. , July 2, 2015 /PRNewswire-USNewswire/ ... and Colton Eakins are gaining invaluable real-world ... Institute of Technology this summer. The students ... Dr. Jeff Wereszczynski,s research group at IIT. ... Professors Dr. Tom Carter , Physics; Dr. ...
(Date:7/1/2015)... ... 2015 , ... It is now possible to separate two common disorders: post-traumatic ... tomography (SPECT) according to researchers from Amen Clinics, UCLA, Thomas Jefferson University, and ... is believed to be the largest brain imaging study ever, will be published on ...
(Date:7/1/2015)... 2015   Neuraltus Pharmaceuticals, Inc. , a privately-held ... drugs to treat neurodegenerative diseases such as amyotrophic ... G. Miller , M.D., Director of the Forbes Norris ... Medical Center in San Francisco, has been awarded a ... to help fund a Phase 2 clinical study ...
Breaking Biology Technology:Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3COD Students Participate in Prestigious Summer Internships 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4
Cached News: